InnoCan Pharma Corporation

InnoCan Pharma Corporation

1.29
USD
-0.01
(-0.77%)
-0.19EPS
7.83MMarket Cap

Total Valuation

USD

As of June 30, 2026, Innocan Pharma Corp. carries a market capitalization of 7.83M, placing it among publicly traded companies globally. Its enterprise value stands at 5.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap7.83M
Enterprise Value5.70M

Share Statistics

As of June 30, 2026, Innocan Pharma Corp. has 4.50M shares outstanding.

Shares Outstanding4.50M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 0.33, and the price-to-book ratio stands at 1.63.

PS Ratio0.33
PB Ratio1.63
P/TBV Ratio1.63
P/FCF Ratio-5.06
P/OCF Ratio-5.12

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 0.24 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 5.70M versus a market cap of 7.83M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.24

Financial Position

As of June 30, 2026, Innocan Pharma Corp. maintains a current ratio of 5.25, meaning it holds 5.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.45, indicating elevated leverage, while an interest coverage ratio of -130.69 demonstrates limited ability to service its debt obligations.

Current Ratio5.25
Quick Ratio3.78
Debt / Equity22.45
Debt / EBITDA-0.49
Interest Coverage-130.69

Financial Efficiency

USD

Over the twelve months ended June 30, 2026, Innocan Pharma Corp. posted a negative return on equity (ROE) of -21.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.95, reflecting losses generated across the asset base. The company generates approximately 2.61M in revenue per employee across its workforce of 9.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.94 indicates how many times Innocan Pharma Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-21.27
Return on Assets (ROA)-8.95
Revenue Per Employee2.61M
Employee Count9.00
Inventory Turnover0.94

Taxes

USD

Over the twelve months ended June 30, 2026, Innocan Pharma Corp. recorded an income tax benefit of -42,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -875,000.00 and -958,000.00 in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-42,000.00

Stock Price Statistics

USD

As of the close on October 26, 2026, Innocan Pharma Corp.'s stock has declined approximately 89.69% over the past 52 weeks. The 50-day moving average sits at 3.50, while the 200-day moving average is 815.96.

52-Week Price Change-89.69%
50-Day Moving Average3.50
200-Day Moving Average815.96

Income Statement

USD

Over the twelve months ended June 30, 2026, Innocan Pharma Corp. generated 23.53M in revenue and converted that into -958,000.00 in net income, yielding earnings per share of -0.19. EBITDA reached -3.40M, while operating income came in at -3.43M.

Revenue23.53M
Gross Profit21.28M
Operating Income-3.43M
Pretax Income-875,000.00
Net Income-958,000.00
EBITDA-3.40M
EBIT-3.43M
Earnings Per Share (EPS)-0.19

Balance Sheet

USD

As of June 30, 2026, Innocan Pharma Corp. holds 6.40M in cash and equivalents against 1.66M in total debt, resulting in a net debt position of -4.73M. Total book value stands at 4.80M, with working capital of 8.33M providing operational flexibility.

Cash & Cash Equivalents6.40M
Total Debt1.66M
Net Debt-4.73M
Equity (Book Value)4.80M
Book Value Per Share1.07
Working Capital8.33M

Cash Flow

USD

Innocan Pharma Corp. produced -1.53M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -19,000.00 in capital expenditures, free cash flow totaled -1.55M - equivalent to -0.34 per share.

Operating Cash Flow-1.53M
Capital Expenditures-19,000.00
Free Cash Flow-1.55M
FCF Per Share-0.34

Margins

Over the twelve months ended June 30, 2026, Innocan Pharma Corp. posted a gross margin of 90.46, reflecting its pricing power and cost economics. The operating margin of -14.60 and net profit margin of -4.07 provide insight into operational efficiency.

Gross Margin90.46
Operating Margin-14.60
Pretax Margin-3.72
Profit Margin-4.07
EBITDA Margin-14.44

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -19.76: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.27, meaning Innocan Pharma Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-8.27
FCF Yield-19.76

Stock Splits

Innocan Pharma Corp.'s most recent stock split took place on September 15, 2025 with a 65:1 split ratio.

Last Split Date9/15/2025
Split Ratio65:1

Scores

As of June 30, 2026, Innocan Pharma Corp. has an Altman Z-Score of -1.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-1.27